Sep 2026· Journal of Alzheimer's Disease· pp.
13872877261488874
· 1 citation· 11 references
Medicine
TL;DR
Lower Aβ42 was associated with subsequent ARIA, but the internally derived cutoff requires external validation, and the internally derived cutoff requires external validation.
Abstract
Amyloid-related imaging abnormalities (ARIA) are a safety concern during lecanemab treatment for early Alzheimer's disease. We examined baseline cerebrospinal fluid amyloid-β 42 (Aβ42) in 97 lecanemab-treated patients; 11 developed ARIA. Aβ42 was lower in ARIA cases than in non-ARIA cases (483.2 ± 108.6 versus 667.4 ± 185.4 pg/mL; p < 0.001). ROC analysis yielded an AUC of 0.806 (95% CI, 0.670-0.919). Aβ40 was also lower, whereas the Aβ42/Aβ40 ratio was not significantly different and tau biomarkers were not higher. Lower Aβ42 was associated with subsequent ARIA, but the internally derived cutoff requires external validation.
BackgroundAlzheimer's disease (AD) is a common progressive neurodegenerative disorder. Lecanemab, an anti-amyloid-β (Aβ) monoclonal antibody, is approved for AD treatment, but real-world efficacy and optimal PET application strategies remain incompletely defined.ObjectiveTo investigate lecanemab's Aβ clearance efficacy...
Z. Qiao, Xiao-Bin Zhao, Gui-Hong Wang et al.· Journal of Alzheimer's Disea...· 0 citations
IMPORTANCE
Predictors of decline and of amyloid-related imaging abnormalities (ARIA) during anti-amyloid β therapy in routine care are undefined.
OBJECTIVE
To identify baseline predictors of cognitive, functional, and safety outcomes.
DESIGN, SETTING, AND PARTICIPANTS
Retrospective cohort of 161 consecutive patient...
Yuki Kujuro, Marina Saito, Manami Maruko et al.· The journal of prevention of...· 0 citations
The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.
Min-Young Noh, Wonjae Sung, Hyunkee Kim et al.· Alzheimer's & Dementia· 0 citations
BackgroundAccurate diagnosis of Alzheimer's disease (AD) in Indonesia remains challenging due to limited access to cerebrospinal fluid (CSF) analysis and PET imaging. Plasma amyloid-β42 (Aβ42) may offer a less-invasive and affordable alternative, particularly when combined with cognitive assessment. However, its diagno...
A. Vidyanti, P. Prawiroharjo, Yuliarni Syafrita et al.· Journal of Alzheimer's Disea...· 0 citations
Lower baseline C3 was consistently associated with ARIA risk across sensitivity analyses and higher baseline C1q with smaller amyloid reduction at week 26, and this association persisted in international normalized ratio (INR)‐adjusted and simplified models.
Gihwan Byeon, Jung-Won Lee, Suhyung Kim et al.· Alzheimer's & Dementia· 0 citations
Plasma p-tau217 is established as a first-choice biomarker for the early detection of AD pathology in specialized clinical settings, displaying excellent diagnostic accuracy and minimal site-related variability.
A. Sánchez-Soblechero, A. Villarejo, M. Carreras et al.· Journal of Alzheimer's Disea...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
